{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:01:17Z","timestamp":1780290077926,"version":"3.54.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    In this study, we explicitly evaluate the anti-inflammatory effects of ivacaftor as a route-of-delivery comparison (intraperitoneal vs. intratracheal) in a reproducible LPS-induced lung inflammation model. We evaluated the effects of ivacaftor [40\u00a0mg\/kg, administered either intraperitoneally (IP) or intratracheally (IT)] on lipopolysaccharide (LPS, 8\u00a0\u03bcg)-induced lung inflammation in 8\u201310-week-old female C57BL\/6 mice. Mice were euthanised at 24 or 72 h post-treatment, and serum, bronchoalveolar lavage fluid (BALF), and lung tissue were collected for analysis. Inflammation was assessed by measuring immune cell infiltration, fluorescence-activated cell sorting (FACS)-based leucocyte profiling, and histological changes. Ivacaftor concentrations in the samples were quantified using multiple reaction monitoring liquid chromatography\u2013mass spectrometry (MRM\u2013LCMS). At 24\u00a0h, both IT and IP ivacaftor significantly reduced the total BALF cell counts (\u223c40% reduction) and neutrophil infiltration compared to the LPS-only controls (\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.05). Inflammatory responses were reduced following ivacaftor treatment, as reflected by lower BALF cellularity, reduced neutrophil infiltration, and improved histological outcomes. Histological analysis showed reduced alveolar wall thickening and immune cell infiltration in ivacaftor-treated lungs. FACS confirmed lower frequencies of neutrophils and macrophages. Ivacaftor concentrations were higher in lung tissue following IT administration. Our findings indicate that ivacaftor has a potential anti-inflammatory effect, unrelated to cystic fibrosis transmembrane conductance regulator (CFTR) function, in a murine model of LPS-induced acute lung injury. These results offer insights into inflammation mechanisms and could inform future clinical treatments.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1787276","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:19:24Z","timestamp":1780287564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing ivacaftor to attenuate LPS-induced acute lung injury: evidence from a non-cystic fibrosis model"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoxuan","family":"Han","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne","place":["Parkville, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne","place":["Parkville, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne","place":["Parkville, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne","place":["Parkville, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"McQuade","sequence":"additional","affiliation":[{"name":"Gut- Laboratory, Department of Medicine Western Health, Melbourne University","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jarnicki","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne","place":["Parkville, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena K.","family":"Schneider-Futschik","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne","place":["Parkville, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1097\/01.ccm.0000057843.47705.e8","article-title":"Neutrophils and acute lung injury","volume":"31","author":"Abraham","year":"2003","journal-title":"Crit. Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1165\/ajrcmb.16.3.9070608","article-title":"Expression and localization of CYP3A4 and CYP3A5 in human lung","volume":"16","author":"Anttila","year":"1997","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1006\/pupt.2000.0231","article-title":"Lipopolysaccharide-induced lung injury in mice. I. Concomitant evaluation of inflammatory cells and haemorrhagic lung damage","volume":"13","author":"Asti","year":"2000","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1164\/ajrccm\/145.6.1477","article-title":"T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis","volume":"145","author":"Azzawi","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1164\/rccm.202002-0369OC","article-title":"Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTR","volume":"202","author":"Birket","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jcf.2015.02.010","article-title":"Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor","volume":"15","author":"Bratcher","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"B7","doi-asserted-by":"publisher","first-page":"eaav3488","DOI":"10.1126\/scitranslmed.aav3488","article-title":"Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis","volume":"11","author":"Esther","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis","volume":"205","author":"Gabillard-Lefort","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1161\/CIRCRESAHA.107.161067","article-title":"Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms","volume":"102","author":"Ganter","year":"2008","journal-title":"Circ. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/acsptsci.9b00060","article-title":"Emerging cystic fibrosis transmembrane conductance regulator modulators as new drugs for cystic fibrosis: a portrait of in vitro pharmacology and clinical translation","volume":"3","author":"Ghelani","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4049\/jimmunol.165.1.139","article-title":"Lipopolysaccharide stimulates the proliferation of human CD56+CD3- NK cells: a regulatory role of monocytes and IL-10","volume":"165","author":"Goodier","year":"2000","journal-title":"J. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"L1093","DOI":"10.1152\/ajplung.00082.2021","article-title":"Ivacaftor partially corrects airway inflammation in a humanized G551D rat","volume":"320","author":"Green","year":"2021","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s0898-6568(00)00149-2","article-title":"LPS induction of gene expression in human monocytes","volume":"13","author":"Guha","year":"2001","journal-title":"Cell Signal"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3390\/pharmaceutics15051488","article-title":"Dry powder inhalation for lung delivery in cystic fibrosis","volume":"15","author":"Han","year":"2023","journal-title":"Pharmaceutics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMc1213681","article-title":"Ivacaftor in a G551D homozygote with cystic fibrosis","volume":"369","author":"Harrison","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.3390\/ijms22147606","article-title":"Anti-inflammatory influences of cystic fibrosis transmembrane conductance regulator drugs on lung inflammation in cystic fibrosis","volume":"22","author":"Harwood","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/acsptsci.2c00007","article-title":"Ivacaftor alters macrophage and lymphocyte infiltration in the lungs following lipopolysaccharide exposure","volume":"5","author":"Harwood","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12951-022-01307-x","article-title":"A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases","volume":"20","author":"He","year":"2022","journal-title":"J. Nanobiotechnology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00318-2019","article-title":"Ivacaftor decreases monocyte sensitivity to interferon-gamma in people with cystic fibrosis","volume":"6","author":"Hisert","year":"2020","journal-title":"ERJ Open Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1365-2249.2001.01456.x","article-title":"Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa","volume":"124","author":"Hubeau","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"B21","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.4049\/jimmunol.151.4.2105","article-title":"Quantitation and kinetics of blood monocyte migration to acute inflammatory reactions, and IL-1 alpha, tumor necrosis factor-alpha, and IFN-gamma","volume":"151","author":"Issekutz","year":"1993","journal-title":"J. Immunol."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"Elife"},{"key":"B23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1513\/AnnalsATS.201802-075FR","article-title":"Cystic fibrosis: translating molecular mechanisms into effective therapies","volume":"15","author":"Jennings","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/genes10030183","article-title":"Progression of cystic fibrosis lung disease from childhood to adulthood: neutrophils, neutrophil extracellular trap (NET) formation, and NET degradation","volume":"10","author":"Khan","year":"2019","journal-title":"Genes (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/1753465813502115","article-title":"Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence","volume":"7","author":"Kotha","year":"2013","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1007\/s00018-020-03540-9","article-title":"Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations","volume":"77","author":"Lara-Reyna","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1128\/iai.70.9.4892-4896.2002","article-title":"Toll-like receptor 4 (TLR4)-deficient murine macrophage cell line as an in vitro assay system to show TLR4-independent signaling of Bacteroides fragilis lipopolysaccharide","volume":"70","author":"Lorenz","year":"2002","journal-title":"Infect. Immun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2201307","DOI":"10.1183\/13993003.01307-2022","article-title":"Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond","volume":"61","author":"Mall","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"L379","DOI":"10.1152\/ajplung.00010.2008","article-title":"Animal models of acute lung injury","volume":"295","author":"Matute-Bello","year":"2008","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00011-022-01657-0","article-title":"Gastrointestinal consequences of lipopolysaccharide-induced lung inflammation","volume":"72","author":"McQuade","year":"2023","journal-title":"Inflamm. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1165\/rcmb.2008-0155OC","article-title":"Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis","volume":"41","author":"Meyer","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s40778-018-0139-3","article-title":"The role of interferon-gamma in hematopoietic stem cell development, homeostasis, and disease","volume":"4","author":"Morales-Mantilla","year":"2018","journal-title":"Curr. Stem Cell Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1002\/ppul.23242","article-title":"Inflammation and its genesis in cystic fibrosis","volume":"50","author":"Nichols","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2005.02256.x","article-title":"Putting the natural killer cell in its place","volume":"117","author":"O'Connor","year":"2006","journal-title":"Immunology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.1021\/bi060490t","article-title":"CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis","volume":"45","author":"Painter","year":"2006","journal-title":"Biochemistry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1164\/ajrccm.155.4.9105054","article-title":"Biological markers of acute lung injury: prognostic and pathogenetic significance","volume":"155","author":"Pittet","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1182\/blood-2014-02-555268","article-title":"A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy","volume":"124","author":"Pohl","year":"2014","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"613170","DOI":"10.3389\/fimmu.2020.613170","article-title":"Alternative pathways of IL-1 activation, and its role in health and disease","volume":"11","author":"Pyrillou","year":"2020","journal-title":"Front. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor and elexacaftor treatment response in cystic fibrosis: a high throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharmacol. and Transl. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/jcph.377","article-title":"Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein","volume":"55","author":"Robertson","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jmr.2447","article-title":"Drug-drug plasma protein binding interactions of ivacaftor","volume":"28","author":"Schneider","year":"2015","journal-title":"J. Mol. Recognit."},{"key":"B44","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1021\/acsinfecdis.6b00035","article-title":"An \u201cUnlikely\u201d pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI","volume":"2","author":"Schneider","year":"","journal-title":"ACS Infect. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jchromb.2016.10.026","article-title":"Development of HPLC and LC\u2013MS\/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO","volume":"1038","author":"Schneider","year":"","journal-title":"J. Chromatogr. B"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3791\/56084","article-title":"Optimized LC-MS\/MS method for the high-throughput analysis of clinical samples of ivacaftor, its major metabolites, and lumacaftor in biological fluids of cystic fibrosis patients","author":"Schneider","year":"2017","journal-title":"J. Vis. Exp."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e75667","DOI":"10.1371\/journal.pone.0075667","article-title":"Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase","volume":"8","author":"Simonin-Le Jeune","year":"2013","journal-title":"PLoS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jcf.2017.03.011","article-title":"CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis","volume":"16","author":"Tarique","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"B49","doi-asserted-by":"publisher","first-page":"114628","DOI":"10.1016\/j.biopha.2023.114628","article-title":"Ivacaftor therapy post myocardial infarction augments systemic inflammation and evokes contrasting effects with respect to tissue inflammation in brain and lung","volume":"162","author":"Vanherle","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1128\/cdli.9.3.530-543.2002","article-title":"Endotoxin-induced gamma interferon production: contributing cell types and key regulatory factors","volume":"9","author":"Varma","year":"2002","journal-title":"Clin. Diagn Lab. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18180","article-title":"Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis","volume":"18","author":"Whiting","year":"2014","journal-title":"Health Technol. Assess."},{"key":"B52","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.immuni.2017.10.021","article-title":"Granulocyte-monocyte progenitors and monocyte-dendritic cell progenitors independently produce functionally distinct monocytes","volume":"47","author":"Yanez","year":"2017","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jcf.2015.02.008","article-title":"Host-pathogen interplay in the respiratory environment of cystic fibrosis","volume":"14","author":"Yonker","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"B54","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1093\/nar\/19.19.5417","article-title":"Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin","volume":"19","author":"Yoshimura","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1787276\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:19:25Z","timestamp":1780287565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1787276\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":55,"alternative-id":["10.3389\/fphar.2026.1787276"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1787276","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1787276"}}